ACM
CRBP icon

ADAR1 Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

ADAR1 Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329K Buy
+35,000
New +$295K 0.02% 231

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ADAR1 Capital Management's CRBP Position: Q1 2026 in Review

ADAR1 Capital Management increased its Corbus Pharmaceuticals (CRBP) stake by 16% in Q1 2026, buying an estimated $379K and bringing the position to 331,781 shares worth $3.12M. The position accounts for 0.18% of the portfolio, ranked #106.

ADAR1 Capital Management first reported a position in CRBP in Q1 2024 and has held it in 6 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • ADAR1 Capital Management held 331,781 shares of Corbus Pharmaceuticals worth $3.12M as of Q1 2026.
  • ADAR1 Capital Management bought 45,000 Corbus Pharmaceuticals shares in Q1 2026, an estimated $379K.
  • Corbus Pharmaceuticals made up 0.18% of ADAR1 Capital Management's portfolio in Q1 2026, its #106 holding.
  • ADAR1 Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.